Peter E. Boyd - 07 Mar 2024 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
SVP, Information Technology, Human Resources and Communications
Signature
/s/ Lori Braender, as Attorney-In-Fact
Issuer symbol
AQST
Transactions as of
07 Mar 2024
Net transactions value
$0
Form type
4
Filing time
11 Mar 2024, 10:35:07 UTC
Previous filing
09 Aug 2023
Next filing
12 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AQST Common Stock Award $0 +86,250 +54% $0.000000 245,998 07 Mar 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AQST Non-Qualified Stock Option (right to buy) Award $0 +43,125 $0.000000 43,125 07 Mar 2024 Common Stock 43,125 $5.68 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
F2 The original Form 4, filed on 3/9/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares for 59,532 shares owned when in fact 59,748 shares of the Issuer's common stock were owned. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an increase in the number of shares reported as beneficially owned by the reporting person by 216 shares.
F3 The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.

Remarks:

SVP, Information Technology, Human Resources and Communications